License and Collaboration Revenues (Tables)

9 Months Ended

Sep. 30, 2022

Revenue Recognition and Deferred Revenue [Abstract]

Summary of License and Collaboration Revenue

License and collaboration revenues are summarized as follows:

	Three Months Ended				Nine Months Ended
	September 30, 2022				September 30, 2022
	Total License and Collaboration Revenues		Percentage of License and Collaboration Revenues		Total License and Collaboration Revenues		Percentage of License and Collaboration Revenues
Sato Agreement - SB206 and SB204	$	646	131.3	%	$	1,939	96.5	%
Prasco Agreement - Cloderm AG	(154)		(31.3)	%	71		3.5	%
License and collaboration revenues	$	492	100.0	%	$	2,010	100.0	%

Schedule of Contract Assets and Contract Liabilities

The following tables present the Company’s contract assets, contract liabilities and deferred revenue balances for the dates indicated.

	Contract Asset		Contract Liability		Net Deferred Revenue
December 31, 2021	$	—	$	13,251	$	13,251
September 30, 2022	$	—	$	11,312	$	11,312
	Short-term Deferred Revenue		Long-term Deferred Revenue		Net Deferred Revenue
December 31, 2021	$	2,586	$	10,665	$	13,251
September 30, 2022	$	2,586	$	8,726	$	11,312